"Designing Growth Strategies is in our DNA"
Region : | Published Date: Upcoming | Report ID: FBI100978| Status : Pipeline
Aspergillosis is a type of infection caused by the mold Aspergillus. Majority of the population inhale spores of Aspergillus almost every day. However, people with respiratory diseases and weak immune systems are more susceptible to get affected by Aspergillus. Aspergillosis is divided into six different types, namely; allergic bronchopulmonary aspergillosis, aspergilloma, allergic aspergillus sinusitis, chronic pulmonary aspergillosis, cutaneous aspergillosis, and invasive aspergillosis. Common symptoms of aspergillosis are fever, cough, running nose, headache, chest pain, coughing up blood, and others.
Current treatment of aspergillosis includes medications and minor surgeries. Oral corticosteroids can be used for the treatment of allergic bronchopulmonary aspergillosis. Anti-fungal medications such as voriconazole and Amphotericin B are effective for the treatment of invasive pulmonary aspergillosis. Also, surgical removal of the fungal mass and embolization is done to stop bleeding in the lungs, which is common in the case of aspergilloma.
According to the Centers for Disease Control and Prevention, 1-15% of the people with cystic fibrosis are likely to develop Allergic bronchopulmonary aspergillosis. The rising prevalence of aspergillosis is increasing the need for effective drugs for the treatment for the infection. Many pharmaceutical companies and government research institutes have been focusing on developing a new treatment for aspergillosis. For instance; Scynexis, Inc. is conducting phase 2 clinical study on SCY-078 for the treatment of aspergillosis.
To get details on market share, speak to our analyst
At present, around 40% of the pipeline candidates for Aspergillosis are in phase 3 clinical stage. Majority of the studies are sponsored by academic research institutes.
The report on ‘Aspergillosis – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Aspergillosis. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Aspergillosis.
The report on ‘Aspergillosis – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.